Market Place
Sourcing Support
Bausch Health Announces Third Quarter 2024 Results
30 Oct 2024 //
ACCESSWIRE
ACG Plenary to Analyze Xifaxan® Risk Reduction in OHE
27 Oct 2024 //
ACCESSWIRE
Bausch Health to Announce Third Quarter 2024 Results on Oct 30, 2024
09 Oct 2024 //
ACCESSWIRE
Bausch Health Survey Highlights Need For Liver Disease Education
08 Oct 2024 //
ACCESSWIRE
Health Canada Approves CABTREO Triple Combo For Acne Vulgaris
11 Sep 2024 //
ACCESSWIRE
Bausch Health Announces Second Quarter 2024 Results
01 Aug 2024 //
ACCESSWIRE
Bausch Health Welcomes Two New Members to the Executive Leadership Team
19 Jul 2024 //
ACCESSWIRE
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
11 Jul 2024 //
ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
20 Jun 2024 //
ACCESSWIRE
Bausch Health Reports R&D Updates Amiselimod Data At Conferences
14 Jun 2024 //
ACCESSWIRE
Bausch Uceris® Canada Listings: For Ulcerative Colitis Treatment
23 May 2024 //
ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
15 May 2024 //
ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
14 May 2024 //
ACCESSWIRE
Bausch Health Announces First Quarter 2024 Results
02 May 2024 //
ACCESSWIRE
Acne Treatment PrARAZLO™ Available Via BC PharmaCare
11 Apr 2024 //
ACCESSWIRE
Court Blocks Norwich`s ANDA Approval Until 2029
11 Apr 2024 //
ACCESSWIRE
Bausch Health to Announce First-Quarter 2024 Results on May 2
11 Apr 2024 //
ACCESSWIRE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
05 Apr 2024 //
ACCESSWIRE
Bausch Health Announces First Public Drug Plan Listings
03 Apr 2024 //
ACCESSWIRE
Based on Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone
02 Apr 2024 //
ACCESSWIRE
Enforcement Report - Week of March 6, 2024
06 Mar 2024 //
FDA
Bausch Health Companies to Present at Cowen Annual Health Care Conference
01 Mar 2024 //
ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
01 Feb 2024 //
ACCESSWIRE
Bausch Health Announces Board Refreshment
01 Feb 2024 //
ACCESSWIRE
Bausch Announces Positive Results From Phase 2 Study Evaluating Amiselimod
21 Dec 2023 //
ACCESSWIRE
Bausch notches win in Xifaxan case against Alvogen
03 Nov 2023 //
FIERCE PHARMA
Bausch Health Announces Third-Quarter 2023 Results
02 Nov 2023 //
ACCESSWIRE
Bausch starts first TV campaign for seasonal depression drug
27 Oct 2023 //
FIERCE PHARMA
FDA Approves Cabtreo(TM) Topical Gel
20 Oct 2023 //
ACCESSWIRE
Analysis Indicates That OHE Patients May Face Delays in Treatment Initiation
17 Oct 2023 //
ACCESSWIRE
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
12 Oct 2023 //
ACCESSWIRE
Salix tackles stigma around brain condition caused by acute liver disease
05 Oct 2023 //
ENDPTS
Bausch Health Announces CFO Transition Plan
18 Sep 2023 //
ACCESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA
11 Sep 2023 //
ACCESSWIRE
Bausch Health Announces Second-Quarter 2023 Results
03 Aug 2023 //
ACCESSWIRE
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
13 Jul 2023 //
ACCESSWIRE
Bausch Health Enters Into $600 Million Financing Facility With KKR
07 Jul 2023 //
ACCESSWIRE
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL`s ™
19 Jun 2023 //
ACCESSWIRE
Bausch Health Responds to Norwich`s ANDA Tentative Approval
06 Jun 2023 //
ACCESSWIRE
New Clinical Study Suggests the Use of OraPharma’s ARESTIN Microspheres
18 May 2023 //
PRESS RELEASE
U.S. District Court Upholds Final Judgment for XIFAXAN® 550 mg
17 May 2023 //
PRESS RELEASE
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
17 May 2023 //
ACCESSWIRE
Bausch Health Observes Mental Health Awareness Month
10 May 2023 //
PRESS RELEASE
Bausch Health, Canada Inc. recalls all lots of Emerade epinephrine
05 May 2023 //
HEALTH CANADA
Bausch Health Announces First-Quarter 2023 Results
04 May 2023 //
PRESS RELEASE
Bausch Health to Announce First-Quarter 2023 Results on May 4
13 Apr 2023 //
ACCESSWIRE
Bausch Health Announces Changes to its Board of Directors
01 Mar 2023 //
ACCESSWIRE
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
23 Feb 2023 //
ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program
13 Feb 2023 //
ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
01 Feb 2023 //
ACCESSWIRE
Bausch + Lomb tackles glaucoma awareness & research funding with nonprofit
05 Jan 2023 //
ENDPTS
Lupin`s Brazil subsidiary acquires 9 brands from Bausch Health
28 Nov 2022 //
ECONOMIC TIMES
Salix Will Present Rifaximin Data at AASLD`s The Liver Meeting(R) 2022
04 Nov 2022 //
ACCESSWIRE
Ortho Dermatologics to Present Data at 2022 Innovations Dermatology Conference
01 Nov 2022 //
ACCESSWIRE
Bausch Health Announces Final Results of Exchange Offers
28 Sep 2022 //
PRNEWSWIRE
Bausch Health Announces Results for Exchange Offers and Consent Solicitations
14 Sep 2022 //
PRNEWSWIRE
Bausch Health Responds to Norwich Tentative FDA Approval for a 200 mg Rifaximin
09 Sep 2022 //
PRNEWSWIRE
Bausch Health Clarifies Release Provisions Related to its Exchange Offers
08 Sep 2022 //
PRNEWSWIRE
Why Shares of Bausch Health Rose as Much as 30.3% This Week
02 Sep 2022 //
FOOL
Bausch Announces Exchange Offers and Consent Solicitations for Senior Notes
30 Aug 2022 //
PRNEWSWIRE
